当前位置: X-MOL 学术Microbiome › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Microbiota from alginate oligosaccharide-dosed mice successfully mitigated small intestinal mucositis.
Microbiome ( IF 13.8 ) Pub Date : 2020-07-25 , DOI: 10.1186/s40168-020-00886-x
Pengfei Zhang 1, 2 , Jing Liu 3 , Bohui Xiong 2 , Cong Zhang 2 , Beining Kang 4 , Yishan Gao 4 , Zengkuan Li 4 , Wei Ge 2 , Shunfeng Cheng 2 , Yanan Hao 2 , Wei Shen 2 , Shuai Yu 5 , Liang Chen 1 , Xiangfang Tang 1 , Yong Zhao 1, 2 , Hongfu Zhang 1
Affiliation  

The increasing incidence of cancer and intestinal mucositis induced by chemotherapeutics are causing worldwide concern. Many approaches such as fecal microbiota transplantation (FMT) have been used to minimize mucositis. However, it is still unknown whether FMT from a donor with beneficial gut microbiota results in more effective intestinal function in the recipient. Recently, we found that alginate oligosaccharides (AOS) benefit murine gut microbiota through increasing “beneficial” microbes to rescue busulfan induced mucositis. In the current investigation, FMT from AOS-dosed mice improved small intestine function over FMT from control mice through the recovery of gene expression and an increase in the levels of cell junction proteins. FMT from AOS-dosed mice showed superior benefits over FMT from control mice on recipient gut microbiotas through an increase in “beneficial” microbes such as Leuconostocaceae and recovery in blood metabolome. Furthermore, the correlation of gut microbiota and blood metabolites suggested that the “beneficial” microbe Lactobacillales helped with the recovery of blood metabolites, while the “harmful” microbe Mycoplasmatales did not. The data confirm our hypothesis that FMT from a donor with superior microbes leads to a more profound recovery of small intestinal function. We propose that gut microbiota from naturally produced AOS-treated donor may be used to prevent small intestinal mucositis induced by chemotherapeutics or other factors in recipients.

中文翻译:

来自藻酸盐低聚糖给药小鼠的微生物群成功缓解了小肠粘膜炎。

化学疗法引起的癌症和肠粘膜炎的发病率增加,引起了全世界的关注。已使用许多方法,例如粪便微生物群移植(FMT)来最小化粘膜炎。然而,尚不清楚来自具有有益肠道菌群的供体的FMT能否在接受者中产生更有效的肠道功能。最近,我们发现藻酸盐低聚糖(AOS)通过增加“有益”微生物来拯救白消安诱发的粘膜炎,从而有益于小鼠肠道菌群。在目前的研究中,通过恢复基因表达和增加细胞连接蛋白的水平,来自AOS给药小鼠的FMT优于对照组小鼠的FMT。通过AOS给药的小鼠的FMT通过“有益”微生物(如白斑球菌)的增加和血液代谢组的恢复,在受体肠道菌群上表现出优于对照小鼠的FMT优势。此外,肠道菌群与血液代谢产物的相关性表明,“有益”微生物乳杆菌有助于血液代谢产物的恢复,而“有害”微生物支原体则没有。数据证实了我们的假设,即来自具有优良微生物的供体的FMT导致小肠功能的更深刻恢复。我们建议,自然产生的经AOS处理的供体的肠道菌群可用于预防受者化疗或其他因素引起的小肠粘膜炎。此外,肠道菌群与血液代谢产物的相关性表明,“有益”微生物乳杆菌有助于血液代谢产物的恢复,而“有害”微生物支原体则没有。数据证实了我们的假设,即来自具有优良微生物的供体的FMT导致小肠功能的更深刻恢复。我们建议,自然产生的经AOS处理的供体的肠道菌群可用于预防受者化疗或其他因素引起的小肠粘膜炎。此外,肠道菌群与血液代谢产物的相关性表明,“有益”微生物乳杆菌有助于血液代谢产物的恢复,而“有害”微生物支原体则没有。数据证实了我们的假设,即来自具有优良微生物的供体的FMT导致小肠功能的更深刻恢复。我们建议,自然产生的经AOS处理的供体的肠道菌群可用于预防受者化疗或其他因素引起的小肠粘膜炎。数据证实了我们的假设,即来自具有优良微生物的供体的FMT导致小肠功能的更深刻恢复。我们建议,自然产生的经AOS处理的供体的肠道菌群可用于预防受者化疗或其他因素引起的小肠粘膜炎。数据证实了我们的假设,即来自具有优良微生物的供体的FMT导致小肠功能的更深刻恢复。我们建议,自然产生的经AOS处理的供体的肠道菌群可用于预防受者化疗或其他因素引起的小肠粘膜炎。
更新日期:2020-07-26
down
wechat
bug